APO Research
Talk to an analyst

APO RESEARCH · REPORT

Unfractionated Heparin

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Unfractionated Heparin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

23 December 2025199 pages

Choose your research edition.

Industry ResearchUnfractionated Heparin Industry Research Report 2026150 pages · $2,950 USDIndustry Growth & TrendsGlobal Unfractionated Heparin Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Unfractionated Heparin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Unfractionated Heparin Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Unfractionated Heparin Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Unfractionated Heparin market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Unfractionated Heparin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Unfractionated Heparin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Unfractionated Heparin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Unfractionated Heparin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Unfractionated Heparin include Shenzhen Techdow Pharmaceutical, Sanofi, Mylan, Jianyou Pharmaceutical, Pfizer, Dongcheng Pharmaceutical, Changshan Pharma, B. Braun and Wellona Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Unfractionated Heparin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Unfractionated Heparin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Unfractionated Heparin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Unfractionated Heparin market size, projected growth trends, production technologies, key applications, and end-use industries.

Unfractionated Heparin Segment by Company

Shenzhen Techdow Pharmaceutical

Sanofi

Mylan

Jianyou Pharmaceutical

Pfizer

Dongcheng Pharmaceutical

Changshan Pharma

B. Braun

Wellona Pharma

Troikaa Pharmaceuticals

Stanex

Sagent Pharmaceuticals, Inc

Rotexmedica GmbH

Rewine Pharmaceutical

Panpharma

Organon Canada

Leo Pharma

Gland Pharma Limited

Bioiberica

Bharat Serums and Vaccines

Unfractionated Heparin Segment by Type

Heparin Sodium

Heparin Calcium

Unfractionated Heparin Segment by Application

Unstable Angina

Pulmonary Embolism (PE)

Deep Vein Thrombosis (DVT)

Atrial Fibrillation-related Clots

Myocardial Infarction

Other

Unfractionated Heparin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Unfractionated Heparin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Unfractionated Heparin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Unfractionated Heparin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Unfractionated Heparin market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Unfractionated Heparin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Unfractionated Heparin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Unfractionated Heparin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Unfractionated Heparin Industry Trends Table 2. Unfractionated Heparin Industry Drivers Table 3. Unfractionated Heparin Industry Opportunities and Challenges Table 4. Unfractionated Heparin Industry Restraints Table 5. Global Unfractionated Heparin Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Unfractionated Heparin Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Unfractionated Heparin Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Unfractionated Heparin Sales Market Share by Manufacturers Table 9. Global Unfractionated Heparin Average Sales Price (USD/unit) of Manufacturers (2021-2026) Table 10. Global Unfractionated Heparin Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Unfractionated Heparin Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Unfractionated Heparin Manufacturers, Product Type & Application Table 13. Global Unfractionated Heparin Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Unfractionated Heparin by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Heparin Sodium Table 17. Major Manufacturers of Heparin Calcium Table 18. Global Unfractionated Heparin Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Unfractionated Heparin Sales by Type (2021-2026) & (k units) Table 20. Global Unfractionated Heparin Sales by Type (2027-2032) & (k units) Table 21. Global Unfractionated Heparin Sales Market Share by Type (2021-2026) Table 22. Global Unfractionated Heparin Sales Market Share by Type (2027-2032) Table 23. Global Unfractionated Heparin Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Unfractionated Heparin Revenue by Type (2021-2026) & (k units) Table 25. Global Unfractionated Heparin Revenue by Type (2027-2032) & (k units) Table 26. Global Unfractionated Heparin Revenue Market Share by Type (2021-2026) Table 27. Global Unfractionated Heparin Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Unstable Angina Table 29. Major Manufacturers of Pulmonary Embolism (PE) Table 30. Major Manufacturers of Deep Vein Thrombosis (DVT) Table 31. Major Manufacturers of Atrial Fibrillation-related Clots Table 32. Major Manufacturers of Myocardial Infarction Table 33. Major Manufacturers of Other Table 34. Global Unfractionated Heparin Sales by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Unfractionated Heparin Sales by Application (2021-2026) & (k units) Table 36. Global Unfractionated Heparin Sales by Application (2027-2032) & (k units) Table 37. Global Unfractionated Heparin Sales Market Share by Application (2021-2026) Table 38. Global Unfractionated Heparin Sales Market Share by Application (2027-2032) Table 39. Global Unfractionated Heparin Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 40. Global Unfractionated Heparin Revenue by Application (2021-2026) & (k units) Table 41. Global Unfractionated Heparin Revenue by Application (2027-2032) & (k units) Table 42. Global Unfractionated Heparin Revenue Market Share by Application (2021-2026) Table 43. Global Unfractionated Heparin Revenue Market Share by Application (2027-2032) Table 44. Global Unfractionated Heparin Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Unfractionated Heparin Sales by Region (2021-2026) & (k units) Table 46. Global Unfractionated Heparin Sales Market Share by Region (2021-2026) Table 47. Global Unfractionated Heparin Sales Forecasted by Region (2027-2032) & (k units) Table 48. Global Unfractionated Heparin Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Unfractionated Heparin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. North America Unfractionated Heparin Sales by Country (2021-2026) & (k units) Table 51. North America Unfractionated Heparin Sales by Country (2027-2032) & (k units) Table 52. Europe Unfractionated Heparin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Europe Unfractionated Heparin Sales by Country (2021-2026) & (k units) Table 54. Europe Unfractionated Heparin Sales by Country (2027-2032) & (k units) Table 55. Asia Pacific Unfractionated Heparin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Asia Pacific Unfractionated Heparin Sales by Country (2021-2026) & (k units) Table 57. Asia Pacific Unfractionated Heparin Sales by Country (2027-2032) & (k units) Table 58. South America, Middle East and Africa Unfractionated Heparin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 59. South America, Middle East and Africa Unfractionated Heparin Sales by Country (2021-2026) & (k units) Table 60. South America, Middle East and Africa Unfractionated Heparin Sales by Country (2027-2032) & (k units) Table 61. Global Unfractionated Heparin Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Unfractionated Heparin Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Unfractionated Heparin Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Unfractionated Heparin Revenue Market Share by Region (2021-2026) Table 65. Global Unfractionated Heparin Revenue Market Share by Region (2027-2032) Table 66. Shenzhen Techdow Pharmaceutical Company Information Table 67. Shenzhen Techdow Pharmaceutical Business Overview Table 68. Shenzhen Techdow Pharmaceutical Unfractionated Heparin Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Shenzhen Techdow Pharmaceutical Unfractionated Heparin Product Portfolio Table 70. Shenzhen Techdow Pharmaceutical Recent Development Table 71. Sanofi Company Information Table 72. Sanofi Business Overview Table 73. Sanofi Unfractionated Heparin Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Sanofi Unfractionated Heparin Product Portfolio Table 75. Sanofi Recent Development Table 76. Mylan Company Information Table 77. Mylan Business Overview Table 78. Mylan Unfractionated Heparin Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Mylan Unfractionated Heparin Product Portfolio Table 80. Mylan Recent Development Table 81. Jianyou Pharmaceutical Company Information Table 82. Jianyou Pharmaceutical Business Overview Table 83. Jianyou Pharmaceutical Unfractionated Heparin Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Jianyou Pharmaceutical Unfractionated Heparin Product Portfolio Table 85. Jianyou Pharmaceutical Recent Development Table 86. Pfizer Company Information Table 87. Pfizer Business Overview Table 88. Pfizer Unfractionated Heparin Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Pfizer Unfractionated Heparin Product Portfolio Table 90. Pfizer Recent Development Table 91. Dongcheng Pharmaceutical Company Information Table 92. Dongcheng Pharmaceutical Business Overview Table 93. Dongcheng Pharmaceutical Unfractionated Heparin Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Dongcheng Pharmaceutical Unfractionated Heparin Product Portfolio Table 95. Dongcheng Pharmaceutical Recent Development Table 96. Changshan Pharma Company Information Table 97. Changshan Pharma Business Overview Table 98. Changshan Pharma Unfractionated Heparin Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Changshan Pharma Unfractionated Heparin Product Portfolio Table 100. Changshan Pharma Recent Development Table 101. B. Braun Company Information Table 102. B. Braun Business Overview Table 103. B. Braun Unfractionated Heparin Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. B. Braun Unfractionated Heparin Product Portfolio Table 105. B. Braun Recent Development Table 106. Wellona Pharma Company Information Table 107. Wellona Pharma Business Overview Table 108. Wellona Pharma Unfractionated Heparin Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Wellona Pharma Unfractionated Heparin Product Portfolio Table 110. Wellona Pharma Recent Development Table 111. Troikaa Pharmaceuticals Company Information Table 112. Troikaa Pharmaceuticals Business Overview Table 113. Troikaa Pharmaceuticals Unfractionated Heparin Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Troikaa Pharmaceuticals Unfractionated Heparin Product Portfolio Table 115. Troikaa Pharmaceuticals Recent Development Table 116. Stanex Company Information Table 117. Stanex Business Overview Table 118. Stanex Unfractionated Heparin Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Stanex Unfractionated Heparin Product Portfolio Table 120. Stanex Recent Development Table 121. Sagent Pharmaceuticals, Inc Company Information Table 122. Sagent Pharmaceuticals, Inc Business Overview Table 123. Sagent Pharmaceuticals, Inc Unfractionated Heparin Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Sagent Pharmaceuticals, Inc Unfractionated Heparin Product Portfolio Table 125. Sagent Pharmaceuticals, Inc Recent Development Table 126. Rotexmedica GmbH Company Information Table 127. Rotexmedica GmbH Business Overview Table 128. Rotexmedica GmbH Unfractionated Heparin Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Rotexmedica GmbH Unfractionated Heparin Product Portfolio Table 130. Rotexmedica GmbH Recent Development Table 131. Rewine Pharmaceutical Company Information Table 132. Rewine Pharmaceutical Business Overview Table 133. Rewine Pharmaceutical Unfractionated Heparin Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Rewine Pharmaceutical Unfractionated Heparin Product Portfolio Table 135. Rewine Pharmaceutical Recent Development Table 136. Panpharma Company Information Table 137. Panpharma Business Overview Table 138. Panpharma Unfractionated Heparin Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Panpharma Unfractionated Heparin Product Portfolio Table 140. Panpharma Recent Development Table 141. Organon Canada Company Information Table 142. Organon Canada Business Overview Table 143. Organon Canada Unfractionated Heparin Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Organon Canada Unfractionated Heparin Product Portfolio Table 145. Organon Canada Recent Development Table 146. Leo Pharma Company Information Table 147. Leo Pharma Business Overview Table 148. Leo Pharma Unfractionated Heparin Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Leo Pharma Unfractionated Heparin Product Portfolio Table 150. Leo Pharma Recent Development Table 151. Gland Pharma Limited Company Information Table 152. Gland Pharma Limited Business Overview Table 153. Gland Pharma Limited Unfractionated Heparin Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. Gland Pharma Limited Unfractionated Heparin Product Portfolio Table 155. Gland Pharma Limited Recent Development Table 156. Bioiberica Company Information Table 157. Bioiberica Business Overview Table 158. Bioiberica Unfractionated Heparin Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 159. Bioiberica Unfractionated Heparin Product Portfolio Table 160. Bioiberica Recent Development Table 161. Bharat Serums and Vaccines Company Information Table 162. Bharat Serums and Vaccines Business Overview Table 163. Bharat Serums and Vaccines Unfractionated Heparin Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 164. Bharat Serums and Vaccines Unfractionated Heparin Product Portfolio Table 165. Bharat Serums and Vaccines Recent Development Table 166. Key Raw Materials Table 167. Raw Materials Key Suppliers Table 168. Unfractionated Heparin Distributors List Table 169. Unfractionated Heparin Customers List Table 170. Research Programs/Design for This Report Table 171. Authors List of This Report Table 172. Secondary Sources Table 173. Primary Sources List of Figures Figure 1. Unfractionated Heparin Product Image Figure 2. Global Unfractionated Heparin Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Unfractionated Heparin Market Size (2021-2032) & (US$ Million) Figure 4. Global Unfractionated Heparin Sales (2021-2032) & (k units) Figure 5. Global Unfractionated Heparin Average Price (USD/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Unfractionated Heparin Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Heparin Sodium Image Figure 9. Heparin Calcium Image Figure 10. Global Unfractionated Heparin Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Unfractionated Heparin Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Unfractionated Heparin Sales Market Share by Type (2021-2032) Figure 13. Global Unfractionated Heparin Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Unfractionated Heparin Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Unfractionated Heparin Revenue Market Share by Type (2021-2032) Figure 16. Unstable Angina Image Figure 17. Pulmonary Embolism (PE) Image Figure 18. Deep Vein Thrombosis (DVT) Image Figure 19. Atrial Fibrillation-related Clots Image Figure 20. Myocardial Infarction Image Figure 21. Other Image Figure 22. Global Unfractionated Heparin Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Unfractionated Heparin Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Unfractionated Heparin Sales Market Share by Application (2021-2032) Figure 25. Global Unfractionated Heparin Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Unfractionated Heparin Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Unfractionated Heparin Revenue Market Share by Application (2021-2032) Figure 28. North America Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 29. North America Unfractionated Heparin Sales Market Share by Country (2021-2032) Figure 30. U.S. Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 31. Canada Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 32. Mexico Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe Unfractionated Heparin Sales Market Share by Country (2021-2032) Figure 35. Germany Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 36. France Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 37. U.K. Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 38. Italy Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 39. Netherlands Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific Unfractionated Heparin Sales Market Share by Country (2021-2032) Figure 42. China Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 43. Japan Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 44. South Korea Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 45. Southeast Asia Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 46. India Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 47. Australia Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa Unfractionated Heparin Sales Market Share by Country (2021-2032) Figure 50. Brazil Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 51. South Africa Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 52. Saudi Arabia Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 53. Turkey Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 54. Argentina Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 55. UAE Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 56. Egypt Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 57. Chile Unfractionated Heparin Sales and Growth Rate (2021-2032) & (k units) Figure 58. Global Unfractionated Heparin Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Unfractionated Heparin Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Unfractionated Heparin Revenue (2021-2032) & (US$ Million) Figure 61. North America Unfractionated Heparin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Unfractionated Heparin Revenue (2021-2032) & (US$ Million) Figure 63. Europe Unfractionated Heparin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Unfractionated Heparin Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Unfractionated Heparin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Unfractionated Heparin Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Unfractionated Heparin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Unfractionated Heparin Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Unfractionated Heparin Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Heparin Sodium
  • Heparin Calcium
Applications
  • Unstable Angina
  • Pulmonary Embolism (PE)
  • Deep Vein Thrombosis (DVT)
  • Atrial Fibrillation-related Clots
  • Myocardial Infarction
  • Other
Companies covered
  • Shenzhen Techdow Pharmaceutical
  • Sanofi
  • Mylan
  • Jianyou Pharmaceutical
  • Pfizer
  • Dongcheng Pharmaceutical
  • Changshan Pharma
  • B. Braun
  • Wellona Pharma
  • Troikaa Pharmaceuticals
  • Stanex
  • Sagent Pharmaceuticals, Inc
  • Rotexmedica GmbH
  • Rewine Pharmaceutical
  • Panpharma
  • Organon Canada
  • Leo Pharma
  • Gland Pharma Limited
  • Bioiberica
  • Bharat Serums and Vaccines

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Unfractionated Heparin Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Unfractionated Heparin Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Unfractionated Heparin Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Unfractionated Heparin Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Unfractionated Heparin Market Dynamics
  1. 2.1 Unfractionated Heparin Industry Trends
  2. 2.2 Unfractionated Heparin Industry Drivers
  3. 2.3 Unfractionated Heparin Industry Opportunities and Challenges
  4. 2.4 Unfractionated Heparin Industry Restraints
3 Unfractionated Heparin Market by Manufacturers
  1. 3.1 Global Unfractionated Heparin Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Unfractionated Heparin Sales by Manufacturers (2021-2026)
  3. 3.3 Global Unfractionated Heparin Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Unfractionated Heparin Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Unfractionated Heparin Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Unfractionated Heparin Manufacturers, Product Type & Application
  7. 3.7 Global Unfractionated Heparin Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Unfractionated Heparin Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Unfractionated Heparin Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Unfractionated Heparin Tier 1, Tier 2, and Tier 3
4 Unfractionated Heparin Market by Type
  1. 4.1 Unfractionated Heparin Type Introduction
  2. 4.1.1 Heparin Sodium
  3. 4.1.2 Heparin Calcium
  4. 4.2 Global Unfractionated Heparin Sales by Type
  5. 4.2.1 Global Unfractionated Heparin Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Unfractionated Heparin Sales by Type (2021-2032)
  7. 4.2.3 Global Unfractionated Heparin Sales Market Share by Type (2021-2032)
  8. 4.3 Global Unfractionated Heparin Revenue by Type
  9. 4.3.1 Global Unfractionated Heparin Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Unfractionated Heparin Revenue by Type (2021-2032)
  11. 4.3.3 Global Unfractionated Heparin Revenue Market Share by Type (2021-2032)
5 Unfractionated Heparin Market by Application
  1. 5.1 Unfractionated Heparin Application Introduction
  2. 5.1.1 Unstable Angina
  3. 5.1.2 Pulmonary Embolism (PE)
  4. 5.1.3 Deep Vein Thrombosis (DVT)
  5. 5.1.4 Atrial Fibrillation-related Clots
  6. 5.1.5 Myocardial Infarction
  7. 5.1.6 Other
  8. 5.2 Global Unfractionated Heparin Sales by Application
  9. 5.2.1 Global Unfractionated Heparin Sales by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Unfractionated Heparin Sales by Application (2021-2032)
  11. 5.2.3 Global Unfractionated Heparin Sales Market Share by Application (2021-2032)
  12. 5.3 Global Unfractionated Heparin Revenue by Application
  13. 5.3.1 Global Unfractionated Heparin Revenue by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Unfractionated Heparin Revenue by Application (2021-2032)
  15. 5.3.3 Global Unfractionated Heparin Revenue Market Share by Application (2021-2032)
6 Global Unfractionated Heparin Sales by Region
  1. 6.1 Global Unfractionated Heparin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Unfractionated Heparin Sales by Region (2021-2032)
  3. 6.2.1 Global Unfractionated Heparin Sales by Region (2021-2026)
  4. 6.2.2 Global Unfractionated Heparin Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Unfractionated Heparin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Unfractionated Heparin Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Unfractionated Heparin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Unfractionated Heparin Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Unfractionated Heparin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Unfractionated Heparin Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Unfractionated Heparin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Unfractionated Heparin Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Unfractionated Heparin Revenue by Region
  1. 7.1 Global Unfractionated Heparin Revenue by Region
  2. 7.1.1 Global Unfractionated Heparin Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Unfractionated Heparin Revenue by Region (2021-2026)
  4. 7.1.3 Global Unfractionated Heparin Revenue by Region (2027-2032)
  5. 7.1.4 Global Unfractionated Heparin Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Unfractionated Heparin Revenue (2021-2032)
  8. 7.2.2 North America Unfractionated Heparin Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Unfractionated Heparin Revenue (2021-2032)
  11. 7.3.2 Europe Unfractionated Heparin Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Unfractionated Heparin Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Unfractionated Heparin Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Unfractionated Heparin Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Unfractionated Heparin Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Shenzhen Techdow Pharmaceutical
  2. 8.1.1 Shenzhen Techdow Pharmaceutical Company Information
  3. 8.1.2 Shenzhen Techdow Pharmaceutical Business Overview
  4. 8.1.3 Shenzhen Techdow Pharmaceutical Unfractionated Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Shenzhen Techdow Pharmaceutical Unfractionated Heparin Product Portfolio
  6. 8.1.5 Shenzhen Techdow Pharmaceutical Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Unfractionated Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Unfractionated Heparin Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Mylan
  14. 8.3.1 Mylan Company Information
  15. 8.3.2 Mylan Business Overview
  16. 8.3.3 Mylan Unfractionated Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Mylan Unfractionated Heparin Product Portfolio
  18. 8.3.5 Mylan Recent Developments
  19. 8.4 Jianyou Pharmaceutical
  20. 8.4.1 Jianyou Pharmaceutical Company Information
  21. 8.4.2 Jianyou Pharmaceutical Business Overview
  22. 8.4.3 Jianyou Pharmaceutical Unfractionated Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Jianyou Pharmaceutical Unfractionated Heparin Product Portfolio
  24. 8.4.5 Jianyou Pharmaceutical Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Unfractionated Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Unfractionated Heparin Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Dongcheng Pharmaceutical
  32. 8.6.1 Dongcheng Pharmaceutical Company Information
  33. 8.6.2 Dongcheng Pharmaceutical Business Overview
  34. 8.6.3 Dongcheng Pharmaceutical Unfractionated Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Dongcheng Pharmaceutical Unfractionated Heparin Product Portfolio
  36. 8.6.5 Dongcheng Pharmaceutical Recent Developments
  37. 8.7 Changshan Pharma
  38. 8.7.1 Changshan Pharma Company Information
  39. 8.7.2 Changshan Pharma Business Overview
  40. 8.7.3 Changshan Pharma Unfractionated Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Changshan Pharma Unfractionated Heparin Product Portfolio
  42. 8.7.5 Changshan Pharma Recent Developments
  43. 8.8 B. Braun
  44. 8.8.1 B. Braun Company Information
  45. 8.8.2 B. Braun Business Overview
  46. 8.8.3 B. Braun Unfractionated Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 B. Braun Unfractionated Heparin Product Portfolio
  48. 8.8.5 B. Braun Recent Developments
  49. 8.9 Wellona Pharma
  50. 8.9.1 Wellona Pharma Company Information
  51. 8.9.2 Wellona Pharma Business Overview
  52. 8.9.3 Wellona Pharma Unfractionated Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Wellona Pharma Unfractionated Heparin Product Portfolio
  54. 8.9.5 Wellona Pharma Recent Developments
  55. 8.10 Troikaa Pharmaceuticals
  56. 8.10.1 Troikaa Pharmaceuticals Company Information
  57. 8.10.2 Troikaa Pharmaceuticals Business Overview
  58. 8.10.3 Troikaa Pharmaceuticals Unfractionated Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Troikaa Pharmaceuticals Unfractionated Heparin Product Portfolio
  60. 8.10.5 Troikaa Pharmaceuticals Recent Developments
  61. 8.11 Stanex
  62. 8.11.1 Stanex Company Information
  63. 8.11.2 Stanex Business Overview
  64. 8.11.3 Stanex Unfractionated Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Stanex Unfractionated Heparin Product Portfolio
  66. 8.11.5 Stanex Recent Developments
  67. 8.12 Sagent Pharmaceuticals, Inc
  68. 8.12.1 Sagent Pharmaceuticals, Inc Company Information
  69. 8.12.2 Sagent Pharmaceuticals, Inc Business Overview
  70. 8.12.3 Sagent Pharmaceuticals, Inc Unfractionated Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sagent Pharmaceuticals, Inc Unfractionated Heparin Product Portfolio
  72. 8.12.5 Sagent Pharmaceuticals, Inc Recent Developments
  73. 8.13 Rotexmedica GmbH
  74. 8.13.1 Rotexmedica GmbH Company Information
  75. 8.13.2 Rotexmedica GmbH Business Overview
  76. 8.13.3 Rotexmedica GmbH Unfractionated Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Rotexmedica GmbH Unfractionated Heparin Product Portfolio
  78. 8.13.5 Rotexmedica GmbH Recent Developments
  79. 8.14 Rewine Pharmaceutical
  80. 8.14.1 Rewine Pharmaceutical Company Information
  81. 8.14.2 Rewine Pharmaceutical Business Overview
  82. 8.14.3 Rewine Pharmaceutical Unfractionated Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Rewine Pharmaceutical Unfractionated Heparin Product Portfolio
  84. 8.14.5 Rewine Pharmaceutical Recent Developments
  85. 8.15 Panpharma
  86. 8.15.1 Panpharma Company Information
  87. 8.15.2 Panpharma Business Overview
  88. 8.15.3 Panpharma Unfractionated Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Panpharma Unfractionated Heparin Product Portfolio
  90. 8.15.5 Panpharma Recent Developments
  91. 8.16 Organon Canada
  92. 8.16.1 Organon Canada Company Information
  93. 8.16.2 Organon Canada Business Overview
  94. 8.16.3 Organon Canada Unfractionated Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Organon Canada Unfractionated Heparin Product Portfolio
  96. 8.16.5 Organon Canada Recent Developments
  97. 8.17 Leo Pharma
  98. 8.17.1 Leo Pharma Company Information
  99. 8.17.2 Leo Pharma Business Overview
  100. 8.17.3 Leo Pharma Unfractionated Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Leo Pharma Unfractionated Heparin Product Portfolio
  102. 8.17.5 Leo Pharma Recent Developments
  103. 8.18 Gland Pharma Limited
  104. 8.18.1 Gland Pharma Limited Company Information
  105. 8.18.2 Gland Pharma Limited Business Overview
  106. 8.18.3 Gland Pharma Limited Unfractionated Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Gland Pharma Limited Unfractionated Heparin Product Portfolio
  108. 8.18.5 Gland Pharma Limited Recent Developments
  109. 8.19 Bioiberica
  110. 8.19.1 Bioiberica Company Information
  111. 8.19.2 Bioiberica Business Overview
  112. 8.19.3 Bioiberica Unfractionated Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Bioiberica Unfractionated Heparin Product Portfolio
  114. 8.19.5 Bioiberica Recent Developments
  115. 8.20 Bharat Serums and Vaccines
  116. 8.20.1 Bharat Serums and Vaccines Company Information
  117. 8.20.2 Bharat Serums and Vaccines Business Overview
  118. 8.20.3 Bharat Serums and Vaccines Unfractionated Heparin Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Bharat Serums and Vaccines Unfractionated Heparin Product Portfolio
  120. 8.20.5 Bharat Serums and Vaccines Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Unfractionated Heparin Value Chain Analysis
  2. 9.1.1 Unfractionated Heparin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Unfractionated Heparin Production Mode & Process
  6. 9.2 Unfractionated Heparin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Unfractionated Heparin Distributors
  9. 9.2.3 Unfractionated Heparin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst